New immunotherapy cocktail shows promise for advanced kidney cancer
NCT ID NCT02210117
First seen Nov 06, 2025 · Last updated May 09, 2026 · Updated 23 times
Summary
This early-phase study tests whether giving immunotherapy drugs (nivolumab alone or with bevacizumab or ipilimumab) before surgery is safe for people with kidney cancer that has spread. About 104 participants will receive these treatments to see how the body reacts and whether the immune system attacks the tumor more effectively. The goal is to find better ways to control the disease, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.